Akanda Corp. is classed by the SEC under Medicinal Chemicals & Botanical Products (industry code 2833), based in New Romney, GB. In its latest annual figures on file, for the fiscal year ended 2024-12-31, it reported revenue of $837 thousand and a loss of $4 million (its filed statements).
Product businessMedicinal Chemicals & Botanical ProductsNew Romney, GBfilings since 20217 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2833, Medicinal Chemicals & Botanical Products); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.4 out of ten, 7 of 9 metrics filed and 2 estimated: past 6.1 out of ten, present 2.9 out of ten, future 4.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 6.0 out of ten. 3 warning events since 2021; the latest 2026-05-01. 60th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 4.4 out of ten. +348.8% a year over 5 filed years; profitable in 0 of 5. 44th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 9.7 out of ten. CrossAssetData estimate 9.7/10, confidence 35 of 100 (one part). 97th percentile among 18 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 1.6 out of ten. ROE -96%: lost 96¢ per shareholder dollar. Leverage 46%: owes 46¢ per asset dollar. 15th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 3.5 out of ten. bottom 35% of 18 in its family; net margin -489.6%. 35th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 12 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 3.7 out of ten. bottom 37% of 18 in its family for room to expand. 37th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.8 out of ten. top 42% of 18 in its family for growth drivers. 58th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 5.3 out of ten. top 47% of 18 in its family for expectations against reality. 53rd percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-06-09 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form F-1, 2026-10-01. Filings on record since 2021. Read from EDGAR 2026-10-12.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.